There are potential risks of the Hemospray powder adhering to the distal end of the endoscope, which can result in adhesion of the endoscope to tissue and consequent difficulty or inability…
There is a rare potential for reduced- or no-energy output during high voltage (HV) therapy (typically 0-12J) in implantable cardioverter defibrillators (ICDs) and cardiac resynchronization…
Class IFDA: OngoingMedtronic Inc., Cardiac Rhythm and Heart Failure (CRHF)
There is a rare potential for reduced- or no-energy output during high voltage (HV) therapy (typically 0-12J) in implantable cardioverter defibrillators (ICDs) and cardiac resynchronization…
Class IFDA: OngoingMedtronic Inc., Cardiac Rhythm and Heart Failure (CRHF)
There is a rare potential for reduced- or no-energy output during high voltage (HV) therapy (typically 0-12J) in implantable cardioverter defibrillators (ICDs) and cardiac resynchronization…
Class IFDA: OngoingMedtronic Inc., Cardiac Rhythm and Heart Failure (CRHF)
There is a rare potential for reduced- or no-energy output during high voltage (HV) therapy (typically 0-12J) in implantable cardioverter defibrillators (ICDs) and cardiac resynchronization…
Class IFDA: OngoingMedtronic Inc., Cardiac Rhythm and Heart Failure (CRHF)
There is a rare potential for reduced- or no-energy output during high voltage (HV) therapy (typically 0-12J) in implantable cardioverter defibrillators (ICDs) and cardiac resynchronization…
Class IFDA: OngoingMedtronic Inc., Cardiac Rhythm and Heart Failure (CRHF)
There is a rare potential for reduced- or no-energy output during high voltage (HV) therapy (typically 0-12J) in implantable cardioverter defibrillators (ICDs) and cardiac resynchronization…
Class IFDA: OngoingMedtronic Inc., Cardiac Rhythm and Heart Failure (CRHF)
There is a rare potential for reduced- or no-energy output during high voltage (HV) therapy (typically 0-12J) in implantable cardioverter defibrillators (ICDs) and cardiac resynchronization…
Class IFDA: OngoingMedtronic Inc., Cardiac Rhythm and Heart Failure (CRHF)
There is a rare potential for reduced- or no-energy output during high voltage (HV) therapy (typically 0-12J) in implantable cardioverter defibrillators (ICDs) and cardiac resynchronization…
Class IFDA: OngoingMedtronic Inc., Cardiac Rhythm and Heart Failure (CRHF)
There is a rare potential for reduced- or no-energy output during high voltage (HV) therapy (typically 0-12J) in implantable cardioverter defibrillators (ICDs) and cardiac resynchronization…
Class IFDA: OngoingMedtronic Inc., Cardiac Rhythm and Heart Failure (CRHF)
There is a rare potential for reduced- or no-energy output during high voltage (HV) therapy (typically 0-12J) in implantable cardioverter defibrillators (ICDs) and cardiac resynchronization…
Class IFDA: OngoingMedtronic Inc., Cardiac Rhythm and Heart Failure (CRHF)
There is a rare potential for reduced- or no-energy output during high voltage (HV) therapy (typically 0-12J) in implantable cardioverter defibrillators (ICDs) and cardiac resynchronization…
Class IFDA: OngoingMedtronic Inc., Cardiac Rhythm and Heart Failure (CRHF)
There is a rare potential for reduced- or no-energy output during high voltage (HV) therapy (typically 0-12J) in implantable cardioverter defibrillators (ICDs) and cardiac resynchronization…
Class IFDA: OngoingMedtronic Inc., Cardiac Rhythm and Heart Failure (CRHF)
There is a rare potential for reduced- or no-energy output during high voltage (HV) therapy (typically 0-12J) in implantable cardioverter defibrillators (ICDs) and cardiac resynchronization…
Class IFDA: OngoingMedtronic Inc., Cardiac Rhythm and Heart Failure (CRHF)
Complaints on clip deployment occurring during clinical procedures, leading to hazardous situations where clips fail to achieve their expected function or deploy incorrectly, potentially…
Class IIFDA: OngoingOlympus Corporation of the Americas
There is a rare potential for reduced- or no-energy output during high voltage (HV) therapy (typically 0-12J) in implantable cardioverter defibrillators (ICDs) and cardiac resynchronization…
Class IFDA: OngoingMedtronic Inc., Cardiac Rhythm and Heart Failure (CRHF)
Medtronic has identified that the logfiles downloaded from the recently updated Model 1521 monitors (Serial Numbers: MON4xxxxxx for OUS and MON5xxxxxx for US), are unable to be processed by…
There is a rare potential for reduced- or no-energy output during high voltage (HV) therapy (typically 0-12J) in implantable cardioverter defibrillators (ICDs) and cardiac resynchronization…
Class IFDA: OngoingMedtronic Inc., Cardiac Rhythm and Heart Failure (CRHF)
There is a rare potential for reduced- or no-energy output during high voltage (HV) therapy (typically 0-12J) in implantable cardioverter defibrillators (ICDs) and cardiac resynchronization…
Class IFDA: OngoingMedtronic Inc., Cardiac Rhythm and Heart Failure (CRHF)
There is a rare potential for reduced- or no-energy output during high voltage (HV) therapy (typically 0-12J) in implantable cardioverter defibrillators (ICDs) and cardiac resynchronization…
Class IFDA: OngoingMedtronic Inc., Cardiac Rhythm and Heart Failure (CRHF)
There is a rare potential for reduced- or no-energy output during high voltage (HV) therapy (typically 0-12J) in implantable cardioverter defibrillators (ICDs) and cardiac resynchronization…
Class IFDA: OngoingMedtronic Inc., Cardiac Rhythm and Heart Failure (CRHF)
There is a rare potential for reduced- or no-energy output during high voltage (HV) therapy (typically 0-12J) in implantable cardioverter defibrillators (ICDs) and cardiac resynchronization…
Class IFDA: OngoingMedtronic Inc., Cardiac Rhythm and Heart Failure (CRHF)
There is a rare potential for reduced- or no-energy output during high voltage (HV) therapy (typically 0-12J) in implantable cardioverter defibrillators (ICDs) and cardiac resynchronization…
Class IFDA: OngoingMedtronic Inc., Cardiac Rhythm and Heart Failure (CRHF)
About the 2023 recall archive
This archive groups records by their reported or recall date. It does not imply that every recall was initiated, announced and resolved during the same calendar year. Open the individual record for the exact dates and source details supplied by FDA or NHTSA.